MarÃ-a DÃ-ez-Campelo

List of Publications by Year
in descending order

26 papers	877 citations	840119 11 h-index	580395 25 g-index
28 all docs	28 docs citations	28 times ranked	1233 citing authors

#	Article	IF	Citations
1	Neutrophil and platelet increases with luspatercept in lower-risk MDS: secondary endpoints from the MEDALIST trial. Blood, 2022, 139, 624-629.	0.6	12
2	Luspatercept for myelodysplastic syndromes/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis. Leukemia, 2022, 36, 1432-1435.	3.3	5
3	Guiding the global evolution of cytogenetic testing for hematologic malignancies. Blood, 2022, 139, 2273-2284.	0.6	29
4	Pevonedistat plus azacitidine vs azacitidine alone in higher-risk MDS/chronic myelomonocytic leukemia or low-blast-percentage AML. Blood Advances, 2022, 6, 5132-5145.	2.5	43
5	Co-occurrence of cohesin complex and Ras signaling mutations during progression from myelodysplastic syndromes to secondary acute myeloid leukemia. Haematologica, 2021, 106, 2215-2223.	1.7	12
6	Daratumumab in transfusionâ€dependent patients with low or intermediateâ€<scp>1</scp> risk myelodysplastic syndromes. American Journal of Hematology, 2021, 96, E111-E114.	2.0	0
7	Analysis of Intratumoral Heterogeneity in Myelodysplastic Syndromes with Isolated del(5q) Using a Single Cell Approach. Cancers, 2021, 13, 841.	1.7	5
8	Multicenter Next-Generation Sequencing Studies between Theory and Practice. Journal of Molecular Diagnostics, 2021, 23, 347-357.	1.2	1
9	Myelodysplastic syndromes with 20q deletion: incidence, prognostic value and impact on response to azacitidine of ASXL1 chromosomal deletion and genetic mutations. British Journal of Haematology, 2021, 194, 708-717.	1.2	7
10	Randomized phase 2 trial of pevonedistat plus azacitidine versus azacitidine for higher-risk MDS/CMML or low-blast AML. Leukemia, 2021, 35, 2119-2124.	3.3	74
11	Luspatercept in Patients with Lower-Risk Myelodysplastic Syndromes. New England Journal of Medicine, 2020, 382, 140-151.	13.9	335
12	Outcome of lower-risk myelodysplastic syndrome with ring sideroblasts (MDS-RS) after failure of erythropoiesis- stimulating agents. Leukemia Research, 2020, 99, 106472.	0.4	4
13	Distinct mutational pattern of myelodysplastic syndromes with and without 5qâ€“ treated with lenalidomide. British Journal of Haematology, 2020, 189, e133-e137.	1.2	4
14	Genome-wide transcriptomics leads to the identification of deregulated genes after deferasirox therapy in low-risk MDS patients. Pharmacogenomics Journal, 2020, 20, 664-671.	0.9	3
15	A myeloid neoplasm with <scp>FIP1L1â€PDGFRA</scp> presenting as acute myeloid leukemia. American Journal of Hematology, 2020, 95, 1214-1215.	2.0	1
16	The implication of â€˜unknown significanceâ€™ variants in nextâ€generation sequencing in diagnosis and donor selection for allogenic haematopoietic stem cell transplantation. Report of a case of myelodysplastic syndrome with a polymorphism in the tyrosine kinase 2 (TYK2) gene. British Journal of Haematology, 2020, 189, e182-e184.	1.2	0
17	Deferasirox reduces oxidative DNA damage in bone marrow cells from myelodysplastic patients and improves their differentiation capacity. British Journal of Haematology, 2019, 187, 93-104.	1.2	12
18	Blood monitoring of circulating tumor plasma cells by next generation flow in multiple myeloma after therapy. Blood, 2019, 134, 2218-2222.	0.6	66

#	Article	IF	Citations
19	Hidden myelodysplastic syndrome (MDS): A prospective study to confirm or exclude MDS in patients with anemia of uncertain etiology. International Journal of Laboratory Hematology, 2019, 41, 109-117.	0.7	5
20	Azacitidine improves outcome in higherâ€risk <scp>MDS</scp> patients with chromosome 7 abnormalities: a retrospective comparison of <scp>GESMD</scp> and <scp>GFM</scp> registries. British Journal of Haematology, 2018, 181, 350-359.	1.2	11
21	Mesenchymal Stromal Cell Irradiation Interferes with the Adipogenic/Osteogenic Differentiation Balance and Improves Their Hematopoietic-Supporting Ability. Biology of Blood and Marrow Transplantation, 2018, 24, 443-451.	2.0	16
22	Clinical and biological significance of isolated Y chromosome loss in myelodysplastic syndromes and chronic myelomonocytic leukemia. A report from the Spanish MDS Group. Leukemia Research, 2017, 63, 85-89.	0.4	9
23	Outcome of Lower-Risk Patients With Myelodysplastic Syndromes Without 5q Deletion After Failure of Erythropoiesis-Stimulating Agents. Journal of Clinical Oncology, 2017, 35, 1591-1597.	0.8	79
24	Use of newer prognostic indices for patients with myelodysplastic syndromes in the low and intermediate-1 risk categories: a population-based study. Lancet Haematology,the, 2015, 2, e260-e266.	2.2	24
25	Response to lenalidomide in myelodysplastic syndromes with del(5q): influence of cytogenetics and mutations. British Journal of Haematology, 2013, 162, 74-86.	1.2	73
26	Single nucleotide polymorphism array karyotyping: A diagnostic and prognostic tool in myelodysplastic syndromes with unsuccessful conventional cytogenetic testing. Genes Chromosomes and Cancer, 2013, 52, 1167-1177.	1.5	44